No intervention, only for observational studies: No intervention, only for observational studies
Study summary
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Eligibility
Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Previously received treatment with EXG102-031 in the study (EXG102-031-111);
2. Paticipantes are informed consent and willingness to follow protocol procedures.
Exclusion Criteria:
1\. Paticipantes are unwilling or unable to participate in long-term follow-up
Primary outcome measure(s)
long-term safety：the types, severity, and incidence of serious adverse events (SAEs), adverse events (AEs). — 4 years the types, severity, and incidence of serious adverse events (SAEs), adverse events (AEs).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.